Kenneth Bate
CIK 1210238 · President & CEO · last filed 2026-01-23
Kenneth Bate is a President & CEO who has filed 92 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for ATXS, was dated Jan 23, 2026. Across all open-market trades the lifetime net is −$29.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions. 20 SEC filings were submitted jointly with CUBIST PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
MDGL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
40 LANDSDOWNE STREET
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Astria Therapeutics, Inc. (ATXS) Delisted | Director | — | $12.58 | — | $0 | 6 | 2026-01-23 |
| MDGL | Director | 2,657 | $437.74 | $1.16M | -$27.02M | 15 | 2025-11-07 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Director | 375 | $15.00 | $5.6K | $0 | 14 | 2023-01-19 |
| Epizyme, Inc. (EPZM) Delisted | Director | 17,054 | $1.47 | $25.1K | $0 | 9 | 2022-05-19 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | — | $0.00 | — | $0 | 8 | 2021-07-02 |
| Astria Therapeutics, Inc. (CATB) Delisted | Director | — | $8.54 | — | $0 | 7 | 2021-06-02 |
| VNDA | Director | 5,000 | $3.94 | $19.7K | $0 | 3 | 2017-06-19 |
| BMRN | Director | 11,875 | $55.75 | $662.0K | $0 | 5 | 2015-06-18 |
| CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted | Director | 0 | — | — | -$2.00M | 4 | 2015-01-21 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | Director | 7,914 | — | — | -$495.9K | 11 | 2013-06-14 |
| NITROMED INC (NTMD) Delisted | President & CEO | — | — | — | $0 | 2 | 2008-02-14 |
| Coley Pharmaceutical Group, Inc. (COLY) Delisted | Director | — | — | — | $0 | 1 | 2007-06-15 |
Recent Filings
92 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-23 | Astria Therapeutics, Inc. (ATXS) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-11-07 | MDGL | Mixed | — | -$4.63M | EDGAR |
| 2025-11-05 | MDGL | Notice (144) | −16,575 | -$8.03M | EDGAR |
| 2025-08-15 | MDGL | Notice (144) | −10,000 | -$3.65M | EDGAR |
| 2025-08-15 | MDGL | Mixed | — | -$3.49M | EDGAR |
| 2025-06-24 | MDGL | Grant (A) | +715 | $0 | EDGAR |
| 2025-06-12 | Astria Therapeutics, Inc. (ATXS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-02-28 | MDGL | Mixed | — | -$5.80M | EDGAR |
| 2025-02-27 | MDGL | Notice (144) | −20,000 | -$7.13M | EDGAR |
| 2024-06-27 | MDGL | Grant (A) | +714 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.